Harnessing Vδ1+ T cells for next-generation immunotherapy: from mechanistic insights to clinical translation
-
By
-
Fan Wang
-
Jiaxuan Zhao
-
Tongcun Zhang
-
Jiangzhou Shi
-
June 9, 2026
-
Objective:
To explore the biological advantages of Vδ1+ T cells for immunotherapy and analyze their therapeutic potential and challenges in clinical translation.
Key Findings:
- Vδ1+ T cells have distinct advantages over conventional αβ T cells due to their MHC-independent recognition.
- They exhibit potent anti-tumor efficacy with lower cytokine release, reducing the risk of cytokine release syndrome.
- Vδ1+ T cells show enhanced intratumoral infiltration and sustained functionality in immunosuppressive environments.
Interpretation:
Limitations:
- Functional heterogeneity due to subtype diversity.
- Complex antigen recognition mechanisms.
- Technical barriers to clinical translation.
Conclusion:
